Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Lipid Disorder Treatment Market - 2020-2027

Published by DataM Intelligence Product code 1004489
Published Content info 180 Pages
Delivery time: 2 business days
Price
Back to Top
Global Lipid Disorder Treatment Market - 2020-2027
Published: May 10, 2021 Content info: 180 Pages
Description

Market Overview

Lipid disorders refer to a broad spectrum of metabolic conditions that affect blood lipid levels. They are characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of cardiovascular disease. There are several easy ways to lower the lipid disorder levels (LDLs), including avoiding foods that are high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and avoiding smoking. Statins are the commonly prescribed treatment for lipid disorders.

The global lipid disorder treatment market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

The increase in the adoption of sedative lifestyles by consumers has rapidly increased various lifestyle diseases around the globe. The presence of high cholesterol levels along with the increasing developments in the treatment for lipid metabolism disorders will further drive the market. According to information published by World Health Organization report, a third of ischemic heart disease is related to high cholesterol levels. Moreover, smoking and drinking have also lead to a rising prevalence of lipid disorder, which further drives the growth of the lipid disorder treatment market during the forecast period.

Changing Lifestyle and Hectic Schedule

Lipid disorders are mainly caused due to obesity and high cholesterol. Obesity has become a prominent problem among a large chunk of the global population. The changing lifestyle and the increased use of alcohol and junk food have triggered obesity among a considerable populace. This will further augment the global lipid disorder treatment market during the forecast period.

Increase in Level of Triglyceride to Drive the Market Growth

The market for lipid disorder treatment is impacted by developing occurrences of disorders related to LDL and a rise in triglyceride levels in the human body. Lipid disorders are common among the working-class population around the globe, which is caused due to fewer body developments, failed weight control plans, immobile activity, and poor lifestyle and habits, such as excessive smoking and drinking that bring about a rise in cholesterol level.

COVID-19 Impact Analysis

COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has directly impacted the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the lockdown policies have resulted in tremendous losses for the lipid disorder treatment market. Thus, this aspect may harm the growth of the lipid disorder treatment market to a certain extent during the forecast period.

Segment Analysis

Based on the drug type, the lipid disorder treatment market has been classified into atorvastatin, rosuvastatin, fluvastatin, simvastatin, pravastatin, and others.

Atorvastatin to Witness Increased Demand for Lipid Disorder Treatment

The increasing risk of lipid disorders has forced pharmaceutical companies to initiated drug enhancement, new drugs development, and conduct phase trials of these drugs on a large scale. Statins are considered highly effective in lowering the rate of cardiovascular events. many companies are focusing on the mass production of atorvastatin as they are highly effective low-density lipoprotein lowering agents, LDL being the root cause of lipid disorders and associated heart diseases. The consumption of atorvastatin drug is expected to grow significantly during the forecast period

The distribution channel segment is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Retail Pharmacies segment to boost growth during forecast period

The retail pharmacies segment accounted for the largest market share due to the high number of retail pharmacies across the globe. Online pharmacies will witness rapid growth over the forecast period because of rapid digitalization and convenience.

Geographical Analysis

Based on geography, the study analyzes the lipid disorder treatment in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America accounted for the largest share in the global lipid disorder treatment market during the forecast period. Rising prevalence of lipid disorders, cardiovascular diseases, and rising health awareness are factors driving the market in the North American region. Europe accounted for the second-largest regional market. The established presence of pharmaceutical companies and rising awareness and prevalence of lipid disorders in the region are some of the factors that are expected to boost the market growth during the forecast period. Asia Pacific is expected to showcase the highest growth potential for the lipid disorder treatment market during the forecast period. An increase in geriatric population base with high vulnerability to metabolic disorders, sedentary lifestyle, growing prevalence of lipid disorders are some factors promoting lipid disorder treatment market growth in the Asia Pacific.

Competitive Landscape

The lipid disorder treatment market is highly competitive, owing to the presence of big brands. The key lipid disorder treatment players which are contributing to the growth of the global market includes, Mylan Pharmaceuticals, Kowa Pharmaceuticals America, Inc., Teva Pharmaceuticals, Pfizer, Inc., Novartis AG, Astrazeneca Plc, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Emcure Pharmaceuticals Ltd., Wockhardt Limited, and Merck & Co. among others.

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer) is one of the leading biopharmaceutical company across the globe. It is primarily engaged in the research, development and manufacture of drugs and healthcare products. The Company operates its business through two business segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). EH includes branded generics, legacy brands, biosimilars generic sterile injectable products, and infusion systems. EH also includes a research and development organization, as well as its contract manufacturing business. IH emphases on development and commercialization of medicines and vaccines. IH therapeutic areas include internal medicine, oncology, vaccines, inflammation and immunology, rare diseases and consumer healthcare. Its brands include Prevnar 13, Eliquis, Xeljanz, Celebrex, Lipitor, Viagra and Pristiq.

Product Portfolio: The company's product portfolio consists of over 150 products across 15 therapeutic areas. Its top brands include Prevenar 13 Lyrica Eliquis Enbrel Becosules Gelusil and Corex range of products.

Why Purchase the Report?

  • Visualize the yeast extract market segmentation composition by drug type, distribution channel, indication, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the yeast extract market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of yeast extract market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global lipid disorder treatment market report would provide access to an approx. 60 market data table, 61 figures and 270 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1. Global Lipid Disorder Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Lipid Disorder Treatment Market- Market Definition and Overview

3. Global Lipid Disorder Treatment Market- Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Lipid Disorder Treatment Market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of LDL and triglyceride associated lipid disorders
      • 4.1.1.2. Growing prevalence of cardiovascular diseases
      • 4.1.1.3. Changing eating habits and sedentary lifestyle
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent Regulatory Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Lipid Disorder Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Lipid Disorder Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Lipid Disorder Treatment Market- By Drug Class

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 7.3. Market Attractiveness Index, By Drug Class Segment
    • 7.3.1. Atorvastatin*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Rosuvastatin
    • 7.3.3. Fluvastatin
    • 7.3.4. Simvastatin
    • 7.3.5. Pravastatin
    • 7.3.6. Others

8. Global Lipid Disorder Treatment Market- By Indication

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
  • 8.3. Market Attractiveness Index, By Indication Segment
    • 8.3.1. Familial Combined Hyperlipidemia*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Familial Defective Apolipoprotein
    • 8.3.3. Familial Dysbetalipoproteinemia
    • 8.3.4. Familial Hypertriglyceridemia
    • 8.3.5. Heterozygous Familial Hypercholesterolemia
    • 8.3.6. Other Indications

9. Global Lipid Disorder Treatment Market- By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospital Pharmacy*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy

10. Global Lipid Disorder Treatment Market- By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Lipid Disorder Treatment Market- Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Lipid Disorder Treatment Market- Company Profiles

  • 12.1. Pfizer*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck & Co.
  • 12.3. Emcure Pharmaceuticals Ltd.
  • 12.4. Ranbaxy Laboratories Ltd.
  • 12.5. AstraZeneca
  • 12.6. Teva Pharmaceuticals
  • 12.7. Mylan Pharmaceuticals, Inc.
  • 12.8. Kowa Pharmaceuticals America, Inc.
  • 12.9. Novartis AG
  • 12.10. Glenmark Pharmaceuticals Ltd.
  • 12.11. Sun Pharmaceuticals Industries Ltd.
  • 12.12. Wockhardt Limited

LIST NOT EXHAUSTIVE

13. Global Lipid Disorder Treatment Market- Premium Insights

14. Global Lipid Disorder Treatment Market- DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
Back to Top